Pharmaceutical pricing in New Zealand

R Ragupathy, K Kilpatrick, ZUD Babar - Pharmaceutical prices in the 21st …, 2014 - Springer
Abstract All New Zealand residents are covered by a national public health system, and
approximately 80% of all health expenditure is publically financed. A well-regulated system …

Price and utilisation differences for statins between four countries

LP Thai, AI Vitry, JR Moss - Expert review of pharmacoeconomics & …, 2018 - Taylor & Francis
ABSTRACT Introduction: Australia, England, France and New Zealand use different policies
to regulate their medicines market, which can impact on utilisation and price. Objectives: To …

Prostate cancer screening and ethical use of limited resources

R Ragupathy, DB Menkes - The New Zealand Medical Journal …, 2013 - search.proquest.com
THE NEW ZEALAND MEDICAL JOURNAL Page 1 THE NEW ZEALAND MEDICAL JOURNAL
Journal of the New Zealand Medical Association NZMJ 1 November 2013, Vol 126 No 1385; …

Comparing subsidized access to medicines across payer systems

M Wonder, R Milne - PharmacoEconomics, 2013 - Springer
We note the original research article by Ragupathy et al.[1] from New Zealand (NZ) on
access to licensed and subsidized medicines under single-payer systems in the USA, the …

[PDF][PDF] 3 A summary of the original articles featured in this issue

A Connolly, R Freebairn, N Wilson, JA Summers… - nzmj.org.nz
We studied injury-related mortality amongst NZ military forces in the First World War. Out of a
total of 16,703 deaths occurring during the War (28 July 1914 to 11 November 1918), injury …

[PDF][PDF] Rajan Ragupathy, Katri Aaltonen, June

PN Tordoff, D Reith - PharmacoEconomics, 2013 - researchgate.net
Wonder and Milne [1] query whether the Department of Veterans Affairs National Formulary
(VANF) is comparable to the other systems. Each comparator is of course in some way sui …